1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 950494-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 1-cyclopentyl-7-fluoro-4-oxoquinoline-3-carboxylic acid
• CAS: 950494-23-2
• 化学式: C₁₅H₁₄FNO₃
• 分子量: 275.279
• InChiKey: WNGLQRXIKKJRTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 在 potassium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 生成 1-cyclopentyl-7-hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Anti-HIV diarylpyrimidine–quinolone hybrids and their mode of action

  摘要：

  A molecular hybridization approach is a powerful tool in the design of new molecules with improved affinity and efficacy. In this context, a series of diarylpyrimidine-quinolone hybrids were synthesized and evaluated against both wt HIV-1 and mutant viral strains. The most active hybrid 5a displayed an EC50 value of 0.28 +/- 0.07 mu M against HIV-1 IIIB. A couple of enzyme-based assays clearly pinpoint a RT-targeted mechanism of action. Docking studies revealed that these hybrids could be well located in the NNIBP of HIV-1 RT despite the bulky and polar properties of a quinolone 3-carboxylic acid moiety in the molecules. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.03.037
• 作为产物：
  描述：

  ethyl 1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Anti-HIV diarylpyrimidine–quinolone hybrids and their mode of action

  摘要：

  A molecular hybridization approach is a powerful tool in the design of new molecules with improved affinity and efficacy. In this context, a series of diarylpyrimidine-quinolone hybrids were synthesized and evaluated against both wt HIV-1 and mutant viral strains. The most active hybrid 5a displayed an EC50 value of 0.28 +/- 0.07 mu M against HIV-1 IIIB. A couple of enzyme-based assays clearly pinpoint a RT-targeted mechanism of action. Docking studies revealed that these hybrids could be well located in the NNIBP of HIV-1 RT despite the bulky and polar properties of a quinolone 3-carboxylic acid moiety in the molecules. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.03.037

文献信息

• Quinolone derivative or pharmaceutically acceptable salt thereof
  申请人：Astellas Pharma Inc

  公开号：US08133882B2

  公开（公告）日：2012-03-13

  Provided are quinolone derivatives having a lower alkyl or cycloalkyl at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof. Pharmaceutical composition containing the quinolone derivatives and methods of using the compositions are provided.

  提供的是喹诺酮衍生物，其在1位具有较低的烷基或环烷基；在3位具有-N（R0）C（O）-较低烷基烷基-CO2R0，较低烷基烷基-CO2R0，较低烯基烷基-CO2R0，-O-较低烷基烷基-CO2R0，-O-（可能被取代为-CO2R0的较低烷基）芳基或-O-较低烯基烷基-CO2R0（其中R0为H或较低烷基）；在6位具有卤素；在7位具有被环状取代基取代的氨基，或其药学上可接受的盐。提供了含有喹诺酮衍生物的药物组合物和使用该组合物的方法。
• QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1995240B1

  公开（公告）日：2012-02-22
• EP1995240A1
  申请人：——

  公开号：EP1995240A1

  公开（公告）日：2008-11-26
• US8133882B2
  申请人：——

  公开号：US8133882B2

  公开（公告）日：2012-03-13
• US8629126B2
  申请人：——

  公开号：US8629126B2

  公开（公告）日：2014-01-14